Do you discontinue an oral JAK inhibitor if a patient develops eczema herpeticum while on the drug?

Ask a clinical question

Answers grounded in the literature and physician expertise.

Related Questions

What is your approach when a female patient does not want a male MA/scribe present in the exam room but other staff are unavailable?

Would you empirically cover anaerobic organisms when treating non-purulent facial cellulitis if oral source (e.g., mucocutaneous lesion) was suspected?

Do you prefer switching to a biologic with a different mechanism of action such as an IL-17 inhibitor over cycling to another TNF inhibitor in a patient with moderate-to-severe HS who has experienced secondary failure to adalimumab after an initial good response?

About Mednet

A community where doctors find answers to medicine's toughest questions.

Verified, credentialed physicians
45,000+ members across 23 specialties
Free CME and MOC credit

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.